Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Date:7/29/2008

CAMBRIDGE, Mass., July 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the second quarter ended June 30, 2008. At June 30, 2008, Idenix's cash, cash equivalents and marketable securities totaled $80.6 million.

2008 Year-to-Date Business Highlights

-- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of approximately 1.8 log(10) after seven days of treatment in each of the 800 mg, 400 mg and 200 mg dosing cohorts. Patients receiving placebo had a 0.05 log(10) viral load increase over the same treatment period. No treatment-related serious adverse events were reported for any of the patients receiving IDX899 and no patients discontinued the study. Based on the potent antiviral activity of IDX899 observed to date, the study was recently amended to also evaluate a 100 mg/day dose.

-- Idenix has submitted an investigational new drug (IND) application for IDX184, a once-daily, oral nucleotide prodrug candidate for the treatment of chronic hepatitis C, to the United States Food and Drug Administration (FDA) and has initiated a phase I single dose escalation study in healthy volunteers. IDX184 has demonstrated HCV antiviral activity in both in vitro and in vivo preclinical models.

-- Idenix has continued to make progress in its preclinical HCV discovery effort. Clinical candidates from both its HCV pro
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
2. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
6. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
8. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
9. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
10. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
11. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... results from a survey of European physicians at ... on Innovation and Biological Therapies" at the Spanish ... event, hosted by EuropaBio and the Spanish Bioindustry ... of Health, physicians from Spanish oncology and rheumatology ...
(Date:11/26/2014)... (PRWEB) November 25, 2014 SonaCare ... Focused Ultrasound (HIFU) devices, recently participated in the ... Renal Mass 360° .” Key opinion leaders in ... advances related to small renal masses while attendees ... different ablative technologies in hands-on labs. Attendees at ...
(Date:11/26/2014)... West Chester, OH (PRWEB) November 25, 2014 ... International Holdings, has joined the Graphel Carbon Products team ... experience in sales, marketing, and customer service for the ... to add Miles to our team,” stated Dave Trinkley, ... Products. “His wide range of experience in the ...
(Date:11/26/2014)... , Nov. 25, 2014 Bio-Techne Corporation (NASDAQ: ... appointed Robert Gavin to serve in a ... Protein Platforms Division.  Mr. Gavin will be responsible for ... which includes the ProteinSimple business acquired in July 2014 ... San Jose, California -based ProteinSimple develops and ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... NEW YORK, June 23 Medicsight PLC, a,subsidiary of ... an industry,leader in the development of Computer-Aided Detection (CAD) ... and Lucan Toh,(Director of Business Development) will be presenting ... 24th June., The conference will be held from ...
... Cystinosis Foundation Ireland to Host Event June 27-28, ... Corp. ("Raptor" or the "Company") (OTC Bulletin Board:,RPTP), ... clinical,division, will present at the Cystinosis Foundation Ireland,s ... 2008 at the,Hilton Hotel, Dublin City, Charlemont Place, ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... services, today announced Health Canada -- Medical,Device ... of the ATS,Open Pivot(R) AP360(TM) Mechanical Heart ... The ATS AP360 heart valve maximizes ...
Cached Biology Technology:Medicsight to Present at Piper Jaffray Annual Europe Conference 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 2Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 3Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 4Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008 5ATS Medical Announces Canadian Regulatory Approval of the ATS Open Pivot AP360 Mechanical Heart Valve 2
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
(Date:11/5/2014)... diversity in their ability to identify scents and odors. ... their perceptual evaluation of odors, with women outperforming men ... Sex differences in olfactory detection may play a role ... one,s perception of smell, which is naturally linked to ... been suggested to be cognitive or emotional, rather than ...
(Date:11/4/2014)... the right amount of death at the right time ... to new research that could help in understanding animal ... , In a paper in the journal Trends ... and European colleagues conclude that the kind of positive ... of individuals, or mortality, depends on the size and ...
Breaking Biology News(10 mins):UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3The female nose always knows: Do women have more olfactory neurons? 2When less is more: Death in moderation boosts population density in nature 2
... gene that contributes to insulin resistance appears to prevent ... researchers say. Cardiovascular disease is the biggest health ... trying to understand why have knocked out protein tyrosine ... get diabetes. "Even before you have really bad ...
... to move swiftly to pass economic recovery legislation ... including the National Science Foundation (NSF), the Department ... and Space Administration (NASA), and National Institute of ... of the American Recovery and Reinvestment Act included ...
... National Institute of Standards and Technology (NIST) has ... be an important quality assurance tool for measuring ... in dietary supplements. The new Standard Reference Material ... collaboration with the Office of Dietary Supplements (ODS) ...
Cached Biology News:Decreasing insulin resistance prevents obesity-related cardiovascular damage 2Decreasing insulin resistance prevents obesity-related cardiovascular damage 3Basic research critical to America's economic recovery 2New reference material can improve testing of multivitamin tablets 2